Bukti Koresponden Endrinaldi

11.13 ⏱ 81%

[OAMJMS] Submission Acknowledgement

PD   Prof. Dr Mirko Spiroski via SFS -...   1/2/2022
      Endrinaldi, Hirowati Ali, Tofrizal, + 3

Hello,

endri naldi has submitted the manuscript, "Optimization of the duration of the administration of Mesenchymal Stem Cells Wharton's Jelly to the Level of Matrix Metalloproteinase-1 and Transforming Growth Factor- in Osteoarthritis Rat Model" to Open Access Macedonian Journal of Medical Sciences.

If you have any questions, please contact me. Thank you for considering this journal as a venue for your work.

Prof. Dr Mirko Spiroski

Balas ke semua

[OAMJMS] Editor Decision

SH Slavica Hristomanova-Mitkovs... 16/2/2022
Endrinaldi, Hirowati Ali, Tofrizal, + 3

Endrinaldi , Hirowati Ali, Tofrizal , Asterina , Elmatris , Sisca Dwi Yarni (Author):

We have reached a decision regarding your submission to Open Access Macedonian Journal of Medical Sciences, "Optimization of the duration of the administration of Mesenchymal Stem Cells Wharton's Jelly to the Level of Matrix Metalloproteinase-1 and Transforming Growth Factor- in Osteoarthritis Rat Model", Manuscript ID = OJS8838, submitted {$submission}

Our decision is to: accept the revised Manuscript for publishing.

SciRev (https://scirev.org/) offers you the
possibility to share your experience with the

↩ ⌄ Balas ke semua

Silakan masuk ke endrinaldi@med
.unand.ac.id.   **MASUK**

Mesenchymal Stem Cells Wharton's Jelly to the Level of Matrix Metalloproteinase-1 and Transforming Growth Factor- in Osteoarthritis Rat Model", Manuscript ID = OJS8838, submitted {$submission}

Our decision is to: accept the revised Manuscript for publishing.

SciRev (https://scirev.org/) offers you the possibility to share your experience with the scientific review process with your colleagues (left search engine) and to select an efficient journal for submitting your manuscripts (right search engine). Because we would like to increase the quality of the review process, please register and submit your experience with the review process of your article published in Open Access Macedonian Journal of Medical Sciences in the SciRev (https://scirev.org/questionnaire/macedonian-journal-of-medical-sciences/).

↰ ⌄ Balas ke semua

Silakan masuk ke endrinaldi@med.unand.ac.id.　　　　**MASUK**

Optimization of the duration of the administration of Mesenchymal Stem Cells Wharton's Jelly to the Level of Matrix Metalloproteinase-1 and Transforming Growth Factor-β in Osteoarthritis Rat Model

Endrinaldi[1], Hirowati Ali[2], Tofrizal[3], Asterina[1], Elmatris[1], Sisca Dwi Yarni[4]

[1]Department of Biochemistry, Faculty of Medicine, Andalas University, Padang, Indonesia.

[2]Department of Biochemistry, Faculty of Medicine, Andalas University, Padang, Indonesia.

[3]Department of Anatomical Pathology, Faculty of Medicine, Andalas University, Padang, Indonesia.

[4]Biomedical Analyst, Faculty of Medicine, Andalas University, Padang, Indonesia/Biotechnology, Andalas University, Padang, Indonesia.

Abstract

Background: Mesenchymal Stem Cell Wharton's Jelly (MSC-WJ) are promising candidates for osteoarthritis (OA) therapy since they have chondrogenic potential and the ability to form the extracellular matrix. This study aimed to determine the effect of the time giving MSC-WJ on bioactive markers of osteoarthritis.

Methods: The osteoarthritis rat model was treated by intra-articular injection with MSC-WJ and α MEM as a control. Four and eight weeks later performed a histological analysis of cartilage and the determination of the levels of Matrix Metalloproteinase-1(MMP-1) and Transforming growth factor β1 (TGF-β1) in serum by ELISA.

Result: The results showed that administration of MSC-WJ showed improvement in the histological picture of knee joints in experimental animals characterized by an increase in cartilage thickness on the joint surface. The administration of MSC-WJ showed a tendency to decrease MMP-1 serum levels of OA rats treated for 8 weeks, although statistically did not show a significant difference. Whereas administration of MSC-WJ showed a decrease in serum levels of TGF-β1 OA rat treated for 8 weeks.

Conclusion: MSC-WJ can repair damaged knee OA cartilage tissue. The administration of MSC-WJ can reduce serum levels of TGF-β1 OA rats treated for 8 weeks.

Keywords: *Osteoarthritis, Mesenchymal Stem Cell Wharton's Jelly, MMP-1, and TGF-β1*

*Correspondence: Endrinaldi, Department of Biochemistry, Faculty of Medicine, Andalas University, Padang, Indonesia
Email: endrinaldi@med.unand.ac.id

Deleted[Penulis]: length of

Deleted[Penulis]: on

Deleted[Penulis]: Osteoarthritis

Deleted[Penulis]: were

Deleted[Penulis]: ,

Deleted[Penulis]: histological

Deleted[Penulis]: in general

Deleted[Penulis]: rat

Introduction

Osteoarthritis (OA) is the most common chronic joint disease with age. OA is etiologically caused by various factors, including mechanical, biochemical, and genetic, all of which can contribute to OA (1,2). OA affects the knee, hand, hip, and spine joints most of all, which are the most important musculoskeletal joints. Symptoms are often associated with significant functional impairment, as well as signs and symptoms of inflammation, including pain, stiffness, and loss of mobility (3).

The causative factors for OA can alter the chondrocyte-matrix interaction in cartilage and stimulate chondrocytes to synthesize catabolic cytokines (4). As a result of this event, there is an imbalance between degradation and synthesis in the articular joint tissue. Research has shown that chondrocytes produce several inflammatory mediators, such as interleukin-1-beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) in tissue and joint fluid OA. Chondrocytes respond to proinflammatory cytokines by increasing the production of proteinases, prostaglandins, and nitric oxide (NO) (5) which degrade the matrix. Currently, OA development is thought to be regulated in large part by excess matrix metalloproteinase (MMP), which contributes to the degradation of the extracellular matrix, such as MMP-1 and MMP-3 which play an important role in OA development by lowering the extracellular matrix (6). Matrix metalloproteinase-1 is a member of MMP, which is highly responsible for the damage to articular joint tissue because it degrades native collagen, namely collagen types I, II, and III. Increased levels were not only seen in the synovial membrane, synovial fluid, and human cartilage diagnosed with OA (7), but also seen in the serum of OA mice significantly (6).

The degradation and synthesis of normal cartilage matrix molecules are constantly controlled by chondrocytes. Apart from catabolic factors, OA chondrocytes also express anabolic growth factors, such as transforming growth factor (TGF)-β and insulin-like growth factor (IGF) -1 which stimulate extracellular matrix (ECM) production (8). Transforming growth factor β (TGF-β) is a multifunctional cytokine that modulates differentiation, proliferation, and extracellular matrix (ECM) production of various biological tissues (9). However, the role of TGF-β is not only in regulating chondrocyte behavior and cartilage destruction, but also in another feature of OA, namely osteophyte formation. Osteophytes are growths on the margins of the joints that line the joint articulation surfaces and can cause clinical problems (10).

Mesenchymal stem cells (MSCs), are very promising candidates for articular cartilage regeneration and cell-based OA therapy because of their ability to differentiate into chondrogenic lineage cells and the ability to form a matrix (11, 12). In addition, MSCs have immunomodulatory and trophic capacities by secreting anti-inflammatory and growth factors (13), which may improve the inflammatory and catabolic aspects of OA. MSC-based therapy is an action to replace cells that are damaged, lost, or reduced by stem cells that can differentiate into the cells needed and MSC is easy to obtain and has minimal side effects. MSCs can differentiate into various specialized cells of mesoderm origin such as bone cells, cartilage, fat, cardiomyocytes, muscle fibers, and renal tubular cells and differentiate into cells from ectoderm origin, for example, neurons, and endoderm origin cells (endodermal origin), such as hepatocytes and pancreatic cells (14). MSC can suppress the proliferation of inflammatory T cells, resulting in immunomodulatory and anti-inflammatory effects. These immunomodulatory mechanisms give rise to their potential use in autoimmune-mediated inflammatory conditions including inflammatory arthropathies (15). In addition, the results of the study by Koh and Choi (2012)

Deleted[Penulis]: factors

Deleted[Penulis]: a number of

Deleted[Penulis]: factor alpha

Deleted[Penulis]: ,

Deleted[Penulis]: is

Deleted[Penulis]: ,

Deleted[Penulis]: have the ability to

Deleted[Penulis]: have the ability to

showed that intra-articular injection of MSC (derived from the infrapatellar fat pad) is effective in reducing pain and improving knee function in patients with knee OA (16).

Our previous study showed that the optimal time for MSC-WJ therapy has not been achieved to reduce MMP-1 levels, although histologically there has been the repair of cartilage tissue (17). It is expected that from the results of this study, the optimal time will be obtained to decrease the level of MMP-1 which is one of the main proteases in degrading the cartilage matrix, and the therapeutic effect of TGF-β which is one of the factors that functions to maintain cartilage homeostasis.

Methods
Animals and Experimental Design
Male white rats (*Rattus novergicus*) weighing between 250–300 grams. The experimental animals were placed in clean cages, disinfected and free of pathogens, and given standard food in the form of pellets and drinking ad libitum. The experimental animals were adapted for 1 week before treatment.

Osteoarthritis Induction
Osteoarthritis was induced by a single injection of intraarticular iodoacetate into the knee joints of anesthetized rats using intraperitoneal injection of 0.1 ml 10% xylazine and 0.2 ml 10% ketamine (18,19,20). Prepare an MIA solution with a concentration of 20 mg / ml (sterile 0.9% NaCl solvent). After anesthetizing the rat's left leg was bent 90° at the knee. The patellar ligament is felt under the kneecap and is injected into this area. Each rat received 0.05 mL intraarticular injection into the left knee using a glass gas-tight syringe with a 27 gauge 0.5-inch needle (18,21). Thirty osteoarthritis rats (three weeks after induction of MIA, Janusz, *et al.*, 2001) were divided into 5 groups. The early OA group, the OA rat group after 4 weeks, the OA rat group after 8 weeks, the OA rat group was treated with MSC-WJ for 4 weeks and the OA rat group was treated with MSC-WJ for 8 weeks. The treated group of OA rats was given 50 μL of MSC-WJ at a dose of 1×10^6 cells to the left knee, the control group and the untreated group were given complete medium after anesthesia.

Deleted[Penulis]: by means of

Deleted[Penulis]: gas tight

Deleted[Penulis]: 0.5 inch

Deleted[Penulis]: rat

Blood Collection and Knee Joints
Blood and Knee Joints were collected from the early OA group, the OA rat group after 4 weeks, the OA rat group after 8 weeks, the OA rat group was treated with MSC-WJ for 4 weeks and the OA rat group was treated with MSC-WJ for 8 weeks. In addition, the knee joint was also collected from healthy rats.

Flow cytometry Analysis
Mesenchymal stem cells used for the test were passage 3. MSC-WJ passage 1 originated from the human umbilical cord (UC-MSC) obtained from the UPT of Stem Cell Medicine Technology RSCM FKUI. Based on flow cytometry analysis, this MSC-WJ has expression of CD73-APC cell surface markers 99.8%, CD105-PerCP-Cys5.5 95%, and CD90-FITC 99.9%. Then MSC-WJ passage 1 is silenced (developed) and MSC passage 3 is obtained.

Figure 1. Data on Characteristics of Mesenchymal Stem Cells Wharton Jelly. (A) Cells MSC-WJ reach confluence. Scale bar: 500 μM. Photographs of cells taken using a Nikon Ti-S microscope; (B) Data flow cytometry. Forward scatter (FCS) plot & side scatter (SSC) plot. Population gated events (P1): 20,000; (C) Cell surface markers expression: CD73-APC 99.8% and CD105-PerCP-Cy5.5 95%; (D) Cell surface markers expression: CD90-FITC 99.9% and Lin (-) -PE 0.4%

Histological Analysis

The rat knee joint was fixed with 10% formalin buffered phosphate, then decalcified in 8% HCl for 1 week. Furthermore, it is processed into paraffin blocks and cut with a microtome with a thickness of 4 μm. The results of the cutting in the form of a ribbon are placed on the surface of warm water at a temperature of 45 ^{0}C to eliminate folds in the ribbon due to cutting. Each ribbon (strip) was stained with Hematoxylin and Eosin.

Measurement of serum MMP-1 and TGF- β1 by ELISA

Blood was drawn from the orbital sinuses of the rat eyes before being sacrificed and centrifuged at 3000 rpm for 15 minutes. The collected serum was stored at -80 ^{0}C until the time of measurement. Serum MMP-1 and TGF-β1 levels were measured by an ELISA kit (Bioassay Technology Laboratory, China and R&D Systems, Minneapolis, MN, USA). All samples were measured in duplicate.

Examination of MMP-1 Levels

Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature. Determine the number of strips required for the assay. Insert the strips in the framers for use. The unused strips should be stored at 2-8 °C. Add 50 μL of the standard well. Add 40 μL sample to sample wells and then add 10 μL anti-MMP-1 antibody to sample wells, then add 50 μL streptavidin-HRP to sample wells and standard wells (Not blank control well). Mix well. Cover the plate with a shaker. Incubate for 60 minutes at 37 °C. Remove the sealer and wash the plate 5 times with wash buffer. Soak wells with at least 0.35 ml wash buffer for 30 seconds to a minute for each wash. For automated washing, aspirate all wells and wash 5 times with wash buffer, overfilling wells with wash buffer. Blot the plate onto paper towels or other absorbent material. Add 50 μL substrate solution A to each well and then add 50 μL substrate solution B to each well. Incubate plate covered with a new sealer for 10 minutes at 37 °C in the dark. Add 50 μL stop solution to

each well; the blue color will change into yellow immediately. Determine the optical density (OD value) of each well immediately using a microplate reader set a 450 nm within 30 min after adding the stop solution.

Examination of TGF-β1 Levels

Prepare all reagents, standard solutions, control, and activated samples as directed in the previous sections. Remove excess microplate strips from the flate frame, return them to the foil pouch containing the desiccant pack, and reseal. Add 50 µL of Assay Diluent RD1-73 (for serum/plasma samples) to each well. Add 50 µL of Standard, Control, or activated sample per well. Tap the plate gently for one minute. Cover with the adhesive strip provided. Incubate for 2 hours at room temperature. A plate layout is provided to record standards and samples assayed. Aspirate each well and wash, repeating the process three times for a total of four washes. Wash by filling each well with Wash Buffer (400 µL) using a squirt bottle, manifold dispenser, or auto washer. Complete removal of the liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels. Add 100 uL of TGF-β1 Conjugate to each well. Cover with a new adhesive strip. Incubate for 2 hours at room temperature. Repeat the aspiration/wash (as in step 5) with Wash Buffer (400 µL). Add 100 µL of Substrate Solution to each well. Incubate for 30 minutes in the room (protect from light). Add 100 µL of Stop Solution to each well. Gently tap the plate to ensure thorough mixing. Determine the optical density of each well within 30 minutes, using a microplate reader set a 450 nm.

Statistical Analysis

The Cartilage thickness data and MMP-1 were analyzed using the ANOVA test. Data of TGF-β1 were analyzed using a non-parametric procedure (Kruskal Wallis). The data are expressed as the mean $\pm$ SD Test. The p-value <0.05 was said to be statistically significant.

Results

Study of 30 male osteoarthritis rats induced by MIA for 3 weeks. The OA rats were divided into 5 groups, an early OA group, two groups of untreated OA rats, and the other 2 groups treated with MSC-WJ for 4 weeks and 8 weeks.

Histopathology

The results of the histopathological examination of the knee joint tissue showed changes in cartilage thickness (Figure 2).

Deleted[Penulis]: exess

Deleted[Penulis]: serum / plasma

Deleted[Penulis]: autowasher

Deleted[Penulis]: aspiration / wash

Deleted[Penulis]: at

Deleted[Penulis]: p value

Deleted[Penulis]: *Histophatology*

Figure 2. Comparison of histology of genu joint tissue between experimental and treatment groups. Negative control (a, f, k), osteoarthritis positive control 4 weeks (b, g, l), osteoarthritis positive control 8 weeks (c, h, m), osteoarthritis MSC-WJ treatment 4 weeks (d, i, n), and osteoarthritis treated by MSC-WJ 8 weeks (e, j, o). The joint tissue of osteoarthritis animals showed a decrease in joint cartilage thickness with a thin cartilage area (arrow). On MSC-WJ administration, there was an increase in joint cartilage thickness compared to positive controls (OA 4 weeks and OA 8 weeks). Hematoxylin-eosin, 200 µm scale.

Cartilage thickness

Assessment of the thickness of the cartilage using the Betaview program, as well as the Beta 3.1MP Sony Exmor CMOS sensor. The results of the assessment showed a decrease in joint cartilage thickness between the control group and the 4 weeks OA group and the 8 weeks OA group. An increase in cartilage thickness occurred in the OA group treated with MSC-WJ.

Table 1. Effect of MSC-WJ therapy on knee cartilage thickness in OA rats

Groups	Cartilage Thickness (µm)	
	Mean ± SD	p
OA Control	245.833 ± 61.8216	0.0001
OA 4 weeks	124.483 ± 37.2402	
OA 8 weeks	102.433 ± 21.0729	
OA + MSC-WJ 4 weeks	172.867 ± 53.8124	
OA + MSC-WJ 8 weeks	195.600 ± 17.3968	

Table 1 shows that the knee cartilage thickness of the rats was significantly different (p <0.05). Knee cartilage thickness of the rats between the control group and the 4 weeks OA group and the 8 weeks OA rat group showed a significant decrease. Knee cartilage thickness increased after treatment with MSC-WJ. However, a significant increase in knee joint cartilage thickness occurred after the OA mice were treated with MSC-WJ for 8 weeks (Figure 3).

Figure 3. Knee cartilage thickness in various treatment groups

ELISA examination

The blood obtained from the experimental animals was centrifuged and then serum was obtained. Serum before analysis was stored in the refrigerator at -80 ^{0}C. The serum obtained was determined by the level of MMP-1 and TGF- β using the ELISA method. The implementation was carried out at the Biomedical Laboratory of the Faculty of Medicine, Andalas University.

MMP-1

The results of measuring MMP-1 levels using the ELISA method showed a tendency to increase in serum MMP-1 levels of OA rats between the early OA rat group with the 4 weeks OA rat group and the 8 weeks OA rat group. Measurement data were analyzed using the ANOVA test.

Table 2. Effect of MSC-WJ therapy on serum MMP-1 levels in OA rats

Groups	MMP-1 Levels (ng/mL)	
	Mean ± SD	p
Early OA	0.26017 ± 0.05596	0.599
OA 4 weeks	0.28583 ± 0.07827	
OA 8 weeks	0.31950 ± 0.05222	
OA + MSC-WJ 4 weeks	0.29600 ± 0.08249	
OA + MSC-WJ 8 weeks	0.30650 ± 0.05356	

Table 2 shows that the MMP-1 serum levels of OA rats were not significantly different (p> 0.05). MMP-1 serum levels of OA rat between the initial OA group and the 4 weeks OA rat group and the 8 weeks OA rat group showed an increasing trend, but this increase was not significantly different. Levels of MMP-1 between the 4 weeks OA rat group and the OA rat group treated with 4 weeks MSC-WJ showed an increasing trend but did not differ significantly. Meanwhile, MMP-1 levels between the 8 weeks OA rat group and the 8 weeks OA rat group treated with 8 weeks of MSC-WJ showed a decreasing trend but did not differ significantly (Figure 4).

Figure 4. MMP-1 levels in various treatment groups

TGF-β1

The results of measuring TGF- β1 levels using the ELISA method showed a tendency to increase serum TGF- β1 levels in OA rats between the initial OA rat group with the 4 weeks OA rat group and the 8 weeks OA rat group. Measurement data was analyzed using the ANOVA test.

Deleted[Penulis]: were

Table 3. Effect of MSC-WJ therapy on serum TGF- β 1 levels of OA rats using the Kruskal Wallis test.

Deleted[Penulis]: Kruskall

Groups	TGF-β level (ng/mL)	
	Mean ± SD	p
Early OA	38.0433 ± 18.7827	0.004
OA 4 weeks	38.3167 ± 11.9387	
OA 8 weeks	64.9500 ± 27.9312	
OA + MSC-WJ 4 weeks	27.0283 ± 16.3462	
OA + MSC-WJ 8 weeks	19.8200 ± 3.6144	

Table 3 shows that there is a significant difference in TGF-β1 levels between the initial OA rat group and the 8 weeks OA rat group and the OA rat group treated with 8 weeks MSC-WJ. Whereas, between groups of early OA rats with 4 weeks of OA rat and groups of OA rats treated with 4 weeks of MSC-WJ, there was no significant difference (p> 0.05). TGF-β1 levels between the 4 weeks OA rat group and the 8 weeks OA rat group treated with 8 weeks of MSC-WJ showed a significant difference (p <0.05), whereas between the 4 weeks OA rat group with the 8 weeks OA rat group and the OA rat treated with MSC-WJ for 4 weeks had no significant difference (p> 0.05). The levels of TGF-β1 between the 8-week OA rat group and the 4 weeks MSC-WJ-treated OA rat group and the 8 weeks MSC-WJ-treated OA rat group were significant (p <0.05). The levels of TGF-β1 between the 4 weeks MSC-WJ-treated OA group and the 8 weeks MSC-WJ-treated OA group were not found to be any significant difference (p> 0.05) (Figure 5).

Figure 5. MMP-1 levels in various treatment groups

Discussion

Joint Cartilage Thickness

In the induction of osteoarthritis, there is a decrease in cartilage thickness on the surface of the knee joint. With irregular cartilage thinning, there is a joint area with cartilage thinning and erosion. The thickness of the cartilage on the joint surface shows irregularity. In general, the thickness of the cartilage at week eight is slightly lower than at week four. Research conducted by Guzman *et al*., (2003) namely on the 28th day after the knee joint induced MIA an area of cartilage erosion occurred (21). Januz *et al.,* (2001) in their study found the occurrence of cartilage depletion on day 21 after MIA-induced mouse knee (18). Research by Deng *et al.,* (2015) showed an increase in surface irregularities, erosion, and loss of chondrocytes in the middle and deep layers of the OA joint (22).

Treatment with MSC-WJ showed an improvement in the histological features of the knee joint in experimental animals characterized by an increase in cartilage thickness on the joint surface in general. An increase in cartilage thickness was seen between the 8 weeks OA rat group and the 8 weeks OA rat group treated with MSC-WJ 8 weeks. The cartilage thickness that was treated for eight weeks was slightly higher than that for four weeks. The average cartilage thickness is still below the average bone thickness value of healthy animals. In some samples after MSC-WJ administration, areas with irregular cartilage thickness were found, but in general, they gave the impression of improvement. This illustrates an improvement in cartilage which indicates an improvement in chondrocyte cells and an increase in protein synthesis that builds the matrix. Research by Deng *et al.,* (2015) showed that OA joints treated with hyaluronic acid (HA) plus G-CSF-mobilized peripheral blood stem cells (gm-PBSCs) showed a significant reduction, while those treated with HA alone showed only a slight decrease in surface irregularity, erosion, and loss of chondrocytes in the middle and deep layers of the OA joint (22).

MMP-1

Matrix metalloproteinase-1 (MMP-1) is one of the protease enzymes that act to degrade the main cartilage matrix components, such as collagen, aggrecan, protein links, and cartilage oligomeric proteins (23,24). This enzyme also serves to increase the proliferation and migration of MSCs (25). MMP-1 increased its production in the synovial membrane, synovial fluid, and

Deleted[Penulis]: , with

Deleted[Penulis]: MIA induced

Deleted[Penulis]: acts

cartilage of humans with OA (7), as well as in the serum of OA rats (6). The release of MMP-1 protein by human articular chondrocytes is stimulated by IL-1β (26). According to Ponte *et al.,* (2007) that MSC expresses MMP-1 constitutively (27). Meanwhile, according to Chen *et al.,* (2018) stated that MSC apart from expressing MMP-1 constitutive can also be increased by IL-1β (28).

This study showed that serum MMP-1 levels in OA rats treated with MSC-WJ had not shown a decrease at 4 weeks of therapy. MSC-WJ therapy for 8 weeks has shown a tendency to decrease MMP-1 levels, but this has not been significantly different. Research by Saulnier *et al.,* (2015) showed that administering MSC to OA rabbits had not been effective in reducing MMP-1 expression after 2 weeks of MSC injection, but was effective in reducing MMP-1 expression after 8 weeks of injection (29). The results of research by Widowati *et al.,* (2018) showed in vitro that MSC-WJ can reduce MMP-1 levels during the chondrogenesis process (30).

The results of this study indicate that MSC-WJ therapy has not been effective in reducing MMP-1 levels in less than 8 weeks after injection. This was seen at 4 weeks of MSC-WJ therapy which showed a tendency to increase MMP-1. Probably in this period, MSC-WJ synthesized and released MMP-1 to be needed in the migration and proliferation process of MSC (25), the process of MSC differentiation, and the process of apoptosis (31). According to Lejmi *et al.,* (2015) that MSC migration depends on MMP-1 activity (32). Research by Ho *et al.,* (2009) demonstrated that MMP-1 plays an important role in the MSC migration function, via MMP1–PAR axis signaling (33). Voronkina *et al.,* (2017) showed the involvement of MMP-1 in the differentiation process of MSC, namely the visible increase in MMP-1 activity during the differentiation process (34). According to Zhao *et al.,* (2016) stated that the apoptotic process induced by MMP1 is mediated by p38 MAPK (31).

The results showed a trend of decreasing MMP-1 at eight weeks after MSC-WJ therapy. According to the research results of Saulnier *et al.,* (2015) molecular analysis of rabbit synovial tissue showed a tendency to decrease MMP-1, MMP-3, and MMP-13 mRNA levels after 2 months of umbilical cord-mesenchymal stem cells (UC-MSCs) (29).

TGF-β1

The transforming growth factor β (TGF-β) family plays a role plays a vital role in the development and homeostasis of various tissues. They regulate cell proliferation, differentiation, apoptosis, and migration, as well as control ECM synthesis and degradation. In addition, these factors mediate the response of cells and tissues to injury and modulate immune function (35). The induction of TGF-β1 is a response to mechanical stress in chondrocytes. Normal mechanical loading on damaged or overloaded joints in normal joints can stimulate chondrocytes to synthesize and release TGF-β1 in a mouse model OA (36).

This study showed that there was an increase in serum TGF-β1 levels of OA rats between the OA rat control group (group I) with the 4 weeks OA mouse group (group II) and the 8 weeks OA mouse group (group III). Research by Yang *et al.,* (2017) showed that there was an increase in TGF-β1 in OA model mice and lasted for a certain period (37). The induction of TGF-β occurs in response to tissue damage, where TGF-β is an anti-inflammatory that plays an important role in various phases of inflammation (38). In the early phase of OA, upregulation of TGF-β stimulates chondrocyte proliferation in an attempt to repair injured cartilage (39).

According to van der Kraan (2018), TGF-β in normal joints plays an important role as protective in maintaining differentiated chondrocyte phenotype, whereas in OA joints TGF-β will have a detrimental action due to its continued presence at high levels (40). An increase in the

concentration of TGF-β1 in subchondral bone triggers a cascade that leads to the development of osteoarthritis. This occurs because TGF-β plays a different role in the subchondral bone as opposed to its anabolic effect on articular cartilage (41). Research by Zhen *et al.,* (2013) showed that inhibition of TGF-β activity in subchondral bone may have a therapeutic effect (41). Research by Chen *et al.,* (2015) revealed that inhibition of the TGF-β1 signaling pathway could protect the knee joint from arthritis (42). According to Chen *et al.,* (2015) that TGF-β1 is a potential pathogenic factor in the development of OA in adult joints (42). Therefore, inhibition of TGF-β1 activity should be considered in the prevention and treatment of OA.

The levels of TGF-β1 had not decreased significantly after 4 weeks of MSC-WJ therapy. However, the level of TGF-β1 decreased after being treated with MSC-WJ for 8 weeks. Mesenchymal stem cells can act as an anti-inflammatory by reducing the production of pro-inflammatory cytokines which directly inhibit T cell function and proliferation (43), prostaglandin E2 secretion, indolamine 2.3 dioxygenase, TGF-β1, and iNOS. In addition, research by Abou Elkhier *et al.,* (2018) revealed that BMMSC therapy caused a decrease in TGF-β regulation in the OA group of rats compared to the untreated group of OA rats (44).

Conclusion

Based on the results of the study, it can be concluded that the Mesenchymal Stem Cell Wharton Jelly can histologically repair damaged knee cartilage tissue in OA rats. Administration of Mesenchymal Stem Cell Wharton Jelly tended to reduce serum MMP-1 levels in knee osteoarthritis rats at 8 weeks of therapy, but the decrease in MMP-1 levels was not significantly different. However, giving Mesenchymal Stem Cell Wharton Jelly reduced serum TGF-β levels in knee osteoarthritis rats treated for 8 weeks.

Ethics of Study

This research has received ethical consideration and approval from the Research Ethics Committee Team of the Faculty of Medicine, Andalas University with registration number 349/KEP/FK/2019.

Conflict of Interest

None.

Deleted[Penulis]: rat

Correspondence

Dr. Endrinaldi, MS
Department of Biochemistry, Faculty of Medicine, Andalas University, Padang, Indonesia.
E-mail: endrinaldi@med.unand.ac.id

Formatted[Penulis]: German(Germany)

References
1. Martel-Pelletier J. Pathophysiology of osteoarthritis. Osteoarthritis Cartilage 12(Suppl A).2004; S31-S33.
2. Goldring MB. Osteoarthritis and cartilage: the role of cytokines. Curr Rheumatol Rep 2000a;2(6):459-65.
3. Felson DT. Osteoarthritis of the Knee. N Engl J Med. 2006;354(8): 841-848.
4. Goldring MB. 2The Role of the Condrocyte in Osteoarthritis. Arthritis Rheum. 2000b;43(9):1916–1926.
5. Goldring MB and Marcu KB. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther. 2009; 11:224.
6. Yan Z, Xiong J, Zhao C, Qin C, He. Decreasing cartilage damage in a rat model of osteoarthritis by intra-articular injection of deoxycholic acid. Int J Clin Exp Med 2015;8(6):9038-9045.
7. Fahmi H, Pelletier J.-P, Di Battista J. A, Cheung Ü H. S, Fernandes J. C and Martel-Pelletier J. Peroxisome proliferator-activated receptor gamma activators inhibit MMP-1 production in human synovial fibroblasts likely by reducing the binding of the activator protein 1. J. OsteoArthritis Research Society Int. 2002;10 (2) :100-108.
8. Blaney Davidson EN, van der Kraan PM, van den Berg WB. TGF-β and osteoarthritis. OsteoArthritis and Cartilage 2007; 15, 597–604.
9. Roberts AB, and Sporn MB. Transforming growth factor β. Adv. Cancer Res. 1998; 51:107–145.
10. van der Kraan PM, van den Berg WB. Osteophytes: relevance and biology. Osteoarthritis Cartilage. 2007; 15:237–244.
11. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 284: 143-147. 10.1126/science. 1999; 284.5411.143.
12. Kolf CM, Cho E, Tuan RS. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewaland differentiation. Arthritis Res Ther. 2007;9:204.
13. Chen L, Tredget EE, Wu PY, et al. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE. 2008; 3:e1886.
14. Kalaszczynska I and Ferdyn K. Wharton's Jelly Derived Mesenchymal Stem Cells: Future of Regenerative Medicine? Recent Findings and Clinical Significance. BioMed Research International. 2015;Article ID 430847, 11 pages .
15. Djouad F, Bouffi C, Ghannam S, et al. Mesenchymal stem cell: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol. 2009; 5:392–9.

Formatted[Penulis]: German(Germany)

Formatted[Penulis]: German(Germany)

16. Koh YG, Choi Y-J. Infrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis. The Knee. 2012;19: 902–907.

17. Endrinaldi E, Darwin E, Zubir N, Revilla G. The Effect of Mesenchymal Stem Cell Wharton's Jelly on Matrix Metalloproteinase-1 and Interleukin-4 Levels in Osteoarthritis Rat Model. Open Access Macedonian Journal of Medical Sciences. 2019;7(4):529-535.

18. Janusz M. J, Hookfin E. B, Heitmeyer S. A, Woessner J. F, Freemont A. J, Hoyland J. A, Brown K. K, Hsieh L. C, Almstead N. G, De B, Natchus M. G, Pikul S and Taiwo Y. O. Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. J. OsteoArthritis Research Society Int. 2001;9 (8): 751–760.

19. Schuelert N, McDougall JJ. Grading of monosodium iodoacetate-induced osteoarthritis reveals a concentration-dependent sensitization of nociceptors in the knee joint of the rat. Neuroscience Letters. 2009;465: 184–188.

20. Javanmard MZ, Asgari D, Karimipour M, Atabaki F, Farjah G, and Niakani A. Mesenchymal Stem Cells Inhibit Proteoglycan Degeneration in a Rat Model of Osteoarthritis. Gene Cell Tisue. 2015; 2(4): e31011: 1-5.

21. Guzman RE, Evan MG, Bove S, Morenko B, and Kilgore K. Mono-Iodoacetate-Induced Histologic Changes in Subchondral Boneand Articular Cartilage of Rat Femorotibial Joints:An Animal Model of Osteoarthritis. Toxicologic Pathology. 2003; 31(6):619–624, 2003.

22. Deng M-W, Shih-Jung Wei S-J, Yew T-L, Lee P-H, Yang T-Y, Chu H-Y, and Hung S-C. Cell Therapy With G-CSF-Mobilized Stem Cells in a Rat Osteoarthritis Model. Cell Transplantation. 2015; Vol 24, pp. 1085–1096.

23. Stracke JO, Fosang AJ, Last K, Mercuri FA, Pendas AM, Llano E, et al. Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). FEBS Lett. 2000; 478: 52–6.

24. De Groot J, Verzijl N, Marion J. G. Wenting-Van Wijk, Bank RA., Lafeber FP, Bijlsma WJ, and TeKoppele JM. Age-Related Decrease in Susceptibility of Human Articular Cartilage to Matrix Metalloproteinase–Mediated Degradation. Arthritis Rheum. 2001; 44(11): 2562–2571.

25. Almalki SG and Agrawal DK. Effects of matrix metalloproteinases on the fate of mesenchymal stem cells. Stem Cell Research & Therapy. 2016; 7:129

26. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum. 2001; 44:585-94.

27. Ponte AL, Marais E, Gallay N, Langonne A, Delorme B, Herault O, Charbord P, Domenech J. The In Vitro Migration Capacity of Human Bone Marrow Mesenchymal Stem Cells Comparison of Chemokine and Growth Factor Chemotactic Activities. Stem Cells.2007; 25:1737–1745.

28. Chen M-S, Lin C-Y, Chiu Y-H, Chen C-P, Tsai P-J, and Wang H-S. IL-1β-Induced Matrix Metalloprotease-1 Promotes Mesenchymal Stem Cell Migration via PAR1 and G-Protein-Coupled Signaling Pathway. Stem Cells International. 2018; Volume 2018, Article ID 3524759, 11 pages.

29. Saulnier N, Viguier E, Perrier-Groult E, Chenu C, Pillet E, Roger T, Maddens S, Boulocher C. Intra-articular administration of xenogeneic neonatal Mesenchymal Stromal Cells early after meniscal injury down-regulates metalloproteinase gene expression in synovium and

prevents cartilage degradation in a rabbit model of osteoarthritis. Osteoarthritis Cartilage. 2015; 23:122-133.

30. Widowati W, Afifah E, Mozef Tj, Sandra F, Rizal R, Amalia A, Arinta Y, Bachtiar I, Murti H. Effects of insulin-like growth factor-induced Wharton jelly mesenchymal stem cells toward chondrogenesis in anosteoarthritis model. 2018. Iran J Basic Med Sci. 2018; 21:745-752.

31. Zhao S, Zhao Y, Guo J, Fei C, Zheng Q, Li X & Chang C. Downregulation of MMP1 in MDS-derived mesenchymal stromal cells reduces the capacity to restrict MDS cell proliferation. Scientific Reports. 2016; 7:43849.

32. Lejmi E, Perriraz N, Clément S, Morel P, Baertschiger R, Christofilopoulos P, et al. Inflammatory chemokines MIP-1δ and MIP-3α are involved in the migration of multipotent mesenchymal stromal cells induced by hepatoma cells. Stem Cells Dev.2015; 24:1223–35.

33. Ho IAW, Chan KYW, Ng W-H, Guo CM, Hui KM., Cheang P, Lam PYP. Matrix Metalloproteinase 1 Is Necessary for the Migration of Human Bone Marrow-Derived Mesenchymal Stem Cells Toward Human Glioma. Stem Cells. 2009; 27:1366–1375.

34. Voronkina IV, Smagina LV, Krylova TA, Musorina AS, and Poljanskaya GG. Analysis of Matrix Metalloproteinase Activity during Differentiation of Mesenchymal Stem Cells Isolated from Different Tissues of One Donor. Cell and Tissue Biology. 2017; 11(2): 95–103.

35. Javelaud D, Mauviel A. Mammalian transforming growth factor-betas: Smad signaling and physio-pathological roles.Int J Biochem Cell Biol. 2004; Jul;36(7):1161-1165.

36. Xu L, Golshirazian I, Asbury BJ, Li Y. Induction of high temperature requirement A1, a serine protease, by TGF-beta1 in articular chondrocytes of mouse models of OA. Histol Histopathol. 2014; 29:609-618.

37. Yang Y, Zhang D, Bai Y. Effect of TGF-β/Smads signaling in patients with osteoarthritis and osteoarthritis rat model. Int J Clin Exp Med. 2017;10(8):12172-12178.

38. Rodrigues-Díez, R, Rayego-Mateos S, Orejudo M, Aroeira LS, Selgas R, Ortiz A, Egido J, and Ruiz-Ortega M. TGF-Beta Blockade Increases Renal InflammationCaused by the C-Terminal Module of the CCN2. Mediators of Inflammation. 2015; Volume 2015, Article ID 506041, 10 pages.

39. Zhen G, Cao X. Targeting TGF-β signaling in subchondral bone and articular cartilage homeostasis. Trends Pharmacol Sci. 2014; 35:227–236.

40. van der Kraan PM. Differential Role of Transforming Growth Factor-beta in an Osteoarthritic or a Healthy Joint. J Bone Metab. 2018; 25:65-72.

41. Zhen G, Wen C, Jia X, Li Y, Crane JL, Mears SC et al. Inhibition of TGF–β signaling in subchondral bone mesenchymal stem cells attenuates osteoarthritis. Nat Med. 2013; June 19(6): 704–712.

42. Chen R, Mian M, Fu M, Zhao JY, Yang L, Li Y, Xu L. Attenuation of the progression of articular cartilage degeneration by inhibition of TGF-beta1 signaling in a mouse model of osteoarthri-tis. Am J Pathol. 2015; 185: 2875-2885.

43. Aggarwal S and Pittenger M F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105(4): 1815-1822.

44. Abou Elkhier MT, Mohamed NN and Mourad MI. Therapeutic Potential of Intra-Articular Injection of Bone Marrow Mesenchymal Stem Cells on Tempromandibular Joints' Induced Osteoarthritis. An Experimental Study. J Dent Oral Biol. 2018; 3(7): 1150.